MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1

Zhang, Yajie; Xu, Wenxia; Ni, Pan; Li, Aiping; Zhou, Jianwei; Xu, Shiqi

doi:10.7150/ijbs.16529

Cited by 60 publications

(51 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We for the first time observe upregulation of miR-99a, miR-145 and downregulation of miR-18b in PAC-resistant cell line. Upregulation of miR-99a was observed in CIS-resistant gastric cancer cell lines [73] and vincristine-resistant acute lymphoblastic leukemia (ALL) [74]. In contrast to our study, downregulation of miR-145 was observed in PAC-resistant variants of A2780 and SKOV-3 ovarian cancer cell lines [75].…”

Section: Discussioncontrasting

confidence: 99%

The significance of microRNA genes expression in ovarian cancer cell lines resistant to cytotoxic drugs

Kaźmierczak¹,

Jopek²,

Sterzyńska³

et al. 2019

Preprint

View full text Add to dashboard Cite

Ovarian cancer is the most fatal type of gynecological cancer. The main reason for high mortality is the development of drug resistance. It can be related to increased expression of drug transporters and increased expression of extracellular matrix (ECM) proteins. miRNA is a short noncoding RNA that regulates expression of about 60% of genes in the human genome and plays a crucial role in developing cancer, including resistance to chemotherapy.Our foremost aim was to exhibit alterations in the miRNA expression levels in the cisplatin (CIS), paclitaxel (PAC), doxorubicin (DOX), and topotecan (TOP) -resistant variants of W1 sensitive ovarian cancer cell line using miRNA microarray. The second goal was to identify miRNAs responsible for the regulation of drug-resistant genes.According to our observation, alterations in the expression of 40 miRNA genes. The level of expression of 21 genes was upregulated in at least one drug-resistant cell line. The expression of 19 genes was downregulated in at least one drug-resistant cell line. We identified target genes for 22 miRNAs. Target analysis showed that miRNA regulates key genes responsible for drug resistance. Among others, we observed regulation of the ABCB1 (MDR1) gene in the W1PR1 cell line by miR-363 and regulation of the COL3A1 gene in the W1TR cell line by miR-29a.Hence, on the basis of our findings, results indicate that genes responsible for drug resistance development in ovarian cancer can be regulated by miRNA.

show abstract

Section: Discussioncontrasting

confidence: 99%

The significance of microRNA genes expression in ovarian cancer cell lines resistant to cytotoxic drugs

Kaźmierczak¹,

Jopek²,

Sterzyńska³

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Deregulation of specific miRs, associated with tumor development and progression, has been observed in gastric cancer along with drug resistance (7,8). Therefore, investigating the roles of these miRs may help improve the diagnosis and treatment of gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer

Sui

Jiao

Zhai

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Gastric cancer is one of the most common types of human cancer associated with a poor prognosis. MicroRNAs (miRs), a class of non-coding RNAs that are 18–25 nucleotides in length, act as key regulators in gene expression, and have been implicated in various human cancer types. miR-125b has been implicated in the malignant progression of gastric cancer. However, the association between miR-125b expression, clinicopathological characteristics and trastuzumab resistance in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer remains unclear. In the current study, in situ hybridization data demonstrated that 81.8% (108/132) of gastric cancer tissues exhibited positive expression of miR-125b, while only 26.3% (10/38) of non-tumor gastric tissues were miR-125b-positive. Reverse transcription-quantitative polymerase chain reaction data indicated that the expression level of miR-125b was markedly increased in gastric cancer tissues compared with non-cancerous gastric tissues. Furthermore, the miR-125b level was significantly associated with tumor (T) stage, lymph node metastasis, distant metastasis and TNM stage of gastric cancer (P<0.05). Increased miR-125b expression predicated poor prognosis in patients with gastric cancer. For HER2-positive gastric cancer, the upregulation of miR-125b expression was significantly associated with advanced malignant progression, as well as a poor prognosis (P<0.05). Furthermore, data from the present study indicated that the increased miR-125b level was significantly associated with trastuzumab resistance in HER2-positive gastric cancer (P<0.05). Therefore, the current study suggests that miR-125b may become a potential biomarker for predicting prognoses and clinical outcomes in patients with HER2-positive gastric cancer that receive trastuzumab treatment.

show abstract

“…In a current study, miRNA‐132 was verified to promote cisplatin resistance in a GC stem cell‐like Lgr5 cells both in vitro and in vivo, which used to be mediated through the regulation of SIRT1/CREB/ABCG2 signaling pathway . The sensitivity of GC cells to cisplatin can enhance by a low expression level of miR‐99a and miR‐491 through targeting CAPNS1/calpain1/calpain2/caspase‐3/PARP1 signaling pathway directly …”

Section: Mirnas and Drug Resistance In Gcmentioning

confidence: 72%

“…172 The sensitivity of GC cells to cisplatin can enhance by a low expression level of miR-99a and miR-491 through targeting CAPNS1/calpain1/calpain2/ caspase-3/PARP1 signaling pathway directly. 174…”

Section: Role Of Mirnas In Signaling Pathways Of Gcmentioning

confidence: 99%

Dysregulation of miRNAs as a signature for diagnosis and prognosis of gastric cancer and their involvement in the mechanism underlying gastric carcinogenesis and progression

Ahadi

2020

IUBMB Life

View full text Add to dashboard Cite

Gastric cancer (GC) is the second main cause of cancer‐related mortality worldwide. The poor prognosis and survival of GC are due to diagnosis in an advanced, noncurable stage and with a restricted response to chemotherapy. GC is usually monitored in an advanced stage; therefore, the poor prognosis and lower level of survival rate with a restricted response to chemotherapy can be detected. Valuable and sensible biomarkers are urgently needed to display screen patients with a high risk of GC that can complement endoscopic diagnosis. Such biomarkers will enable the efficient prediction of the therapeutic response and prognosis of GC patients and prefer the establishment of an advantageous treatment method for each and every patient. Noninvasive diagnostic biomarkers may additionally make a contribution to the early identification of GC and enhance medical management. MicroRNAs (miRNAs) are a group of small noncoding RNAs that have displayed a strong association with GC. Accumulating evidence indicates that miRNAs are potential biomarkers with more than one diagnostic function for GC. Actually, miRNAs regulate cell proliferation, apoptosis, migration, invasion, and metastasis via many biological pathways through the repression of target mRNAs. The current review is accordingly to spotlight the multifaceted roles of miRNAs in GC, which would provide indications for future research. Therefore, we review right here the aberrant expression of miRNAs and underlying mechanisms, consequent effects due to miRNAs dysregulation, and accountable target genes in GC. Besides, potential clinical applications are also highlighted.

show abstract

MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1

Cited by 60 publications

References 42 publications

The significance of microRNA genes expression in ovarian cancer cell lines resistant to cytotoxic drugs

The significance of microRNA genes expression in ovarian cancer cell lines resistant to cytotoxic drugs

Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer

Dysregulation of miRNAs as a signature for diagnosis and prognosis of gastric cancer and their involvement in the mechanism underlying gastric carcinogenesis and progression

Contact Info

Product

Resources

About